Referring Patients with Sickle Cell Disease to Transplant
This webinar aired on September 7 at 10 AM - 11 AM CT/11 AM - 12 PM ET. It is the first webinar in the new ASTCT & National Marrow Donor Program® (NMDP)/Be The Match® Sickle Cell Webinar Series, in honor of Sickle Cell Awareness month. This first webinar featured presentations from clinicians and patient speakers on the referral process for patients with sickle cell disease to curative options with transplant. Other topics include:
- General principles of referral and consultation
- Psychosocial supports for patients in the referral process
- Successful education models from New Jersey that connect community hematology and oncology physicians and transplant specialists.
This webinar will be moderated by Dr. Maryam Zia, and feature presentations by Ana Gordon, a referral coordinator at University of Illinois at Chicago, and Dr. Jennifer Krajewski, from Hackensack Meridian Health. Each webinar in this series will also highlight patient's lived experiences within each of the topics.
There will be a short Q&A section at the end of the webinar, so be sure to register and submit any questions in advance that you would like answered during the webinar by emailing firstname.lastname@example.org. This webinar will be recorded and the recording and slides will be posted 24-48 hours after the live event.
Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.
Continuing Medical Education Information
This activity is jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy.
Statement of Need:
The Sickle Cell Warriors Program at NMDP is a patient services program that assists in typing for patients, financial assistance, counseling, patient education and providing peer connections. The primary feedback from patients in the Sickle Cell Warrior Program is that #1 barrier to treatment is physicians. Patients report that they are not being told about all of their treatment options; regardless of disease severity, they should at least be made aware of various options, but often they are not. Many patients go to the Sickle Cell Warriors Program to enroll in a clinical trial for transplant, but this usually does not cover cost of HLA typing. In this case, the referring physician has not gone through the process of HLA typing, either because of misinformation or because the physician refuses to provide an order for typing simply because they don’t agree with patients physicians. This is a clear miscommunication between the community oncologists and transplant physicians. In surveys, transplant physicians identify a lack of awareness, lack of confidence, and reliance on outdated data from the referring physicians. These referring physicians in a similar survey reported that their primary reason for not communicating all treatment options was noncompliance in patients who they did not believe had the means to move forward with treatment. This illustrates a complex problem between the three groups (referring community physicians, transplant physicians, and the patients themselves) that this webinar series aims to address.
This activity is intended for physicians, both referring physicians and transplant specialists, scientists, and other healthcare professionals who are part of the multidisciplinary team.
Upon completion of this education activity, participants will be able to:
1. Describe the general principles for referring patients with sickle cell disease to transplant consultations.
2. Identify areas of strengths and gaps for patient’s psychosocial support throughout the referral, decision making, and transplant process.
3. Recognize opportunities for further communication and peer education with community oncologists, hematologists and transplant physicians in order to increase rates of getting sickle cell patients to curative options.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the American Society for Transplantation and Cellular Therapy. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.
The France Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation/How to Receive Credit:
- Review the activity objectives and CME/CE information.
- Participate in the CME/CE activity.
- Complete the CME/CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- If you are requesting educational credits or a certificate of participation, your certificate will be available for download.
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Activity Staff Disclosures:
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.
The planners, reviewers, editors, staff, CME committee, or other members at the American Society for Transplantation and Cellular Therapy who control content have no relevant financial relationships to disclose.
Faculty disclosures will be provided prior to the start of the activity.
Commercial Supporter Disclosures
No commercial support is provided for this webinar.
Disclosure of Unlabeled Use:
TFF and ASTCT require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
The France Foundation and the American Society for Transplantation and Cellular Therapy present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the American Society for Transplantation and Cellular Therapy assume no liability for the information herein.
|Access Date||Quiz Result||Score||Actions|